{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:27:23Z","timestamp":1793114843694,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.cmi.2019.03.030","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T11:42:23Z","timestamp":1555069343000},"page":"932-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients"],"prefix":"10.1016","volume":"25","author":[{"given":"B.","family":"Guti\u00e9rrez-Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rodr\u00edguez-Ba\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.03.030_bib1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","article-title":"Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data","volume":"14","author":"Van Boeckel","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib2","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1128\/AAC.01823-12","article-title":"Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients","volume":"57","author":"Armand-Lef\u00e8vre","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib3","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s10096-014-2094-y","article-title":"Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae","volume":"33","author":"Pilmis","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib4","volume":"vols. 1\u20138","author":"Palacios-baena","year":"2017"},{"key":"10.1016\/j.cmi.2019.03.030_bib5","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2019.03.030_bib6","series-title":"Cochrane methods. Cochrane database syst. Rev","first-page":"29","article-title":"A\u00a0revised tool for assessing risk of bias in randomized trials","author":"Higgins","year":"2016"},{"key":"10.1016\/j.cmi.2019.03.030_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended spectrum beta-lactamases\u202f: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.03.030_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum\u202fbeta-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC \u0392-lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.03.030_bib10","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib11","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1093\/jac\/dky168","article-title":"Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis","volume":"73","author":"Son","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib12","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1128\/AAC.01450-09","article-title":"Worldwide experience with the use of doripenem against extended-spectrum- \u03b2-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies","volume":"54","author":"Kaniga","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijantimicag.2018.04.001","article-title":"Molecular \u03b2-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: efficacies analysed against susceptible and resist","volume":"52","author":"Mendes","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib14","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs. meropenem on 30-day mortality for patients with e coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2019.03.030_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijantimicag.2011.08.018","article-title":"Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence","volume":"39","author":"Nicolau","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib16","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/AAC.06301-11","article-title":"Carbapenem therapy for bacteremia due to extended-spectrum-\u03b2- lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility","volume":"56","author":"Lee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib17","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.ijid.2011.09.019","article-title":"Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli: a propensity score analysis","volume":"16","author":"Wu","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib18","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1128\/AAC.05913-11","article-title":"Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"56","author":"Collins","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib19","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jac\/dkv502","article-title":"Ertapenem for the treatment of bloodstream\u00a0infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study","volume":"71","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2284-1","article-title":"Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial","volume":"17","author":"Rattanaumpawan","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1086\/503264","article-title":"In\u00a0vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended- spectrum b-lactamase","volume":"42","author":"Elliott","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1099\/jmm.0.012468-0","article-title":"Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum \u03b2-lactamase","volume":"59","author":"Skurnik","year":"2010","journal-title":"J\u00a0Med Microbiol"},{"key":"10.1016\/j.cmi.2019.03.030_bib23","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/jac\/dkq152","article-title":"Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-\u03b2lactamase-producing Gram-negative organisms","volume":"65","author":"Bazaz","year":"2010","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib24","volume":"vol 55","author":"Song","year":"2014"},{"key":"10.1016\/j.cmi.2019.03.030_bib25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2016.04.014","article-title":"Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum \u03b2-lactamase urinary tract infections","volume":"48","author":"Veve","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4103\/ijn.IJN_207_17","article-title":"Efficacy and cost comparison of ertapenem as outpatient parenteral antimicrobial therapy in acute pyelonephritis due to extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"28","author":"Ramasubramanian","year":"2018","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.cmi.2019.03.030_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/cir793","article-title":"Can we really use \u00df-lactam\/\u00df-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum \u00df-lactamase- producing bacteria?","volume":"54","author":"Perez","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Correction to: imipenem\u2013relebactam and meropenem\u2013vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2019.03.030_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bjid.2017.03.006","article-title":"Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013\u20132015","volume":"21","author":"Karlowsky","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib30","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10096-018-3274-y","article-title":"Activity of Ertapenem against Enterobacteriaceae in seven global regions\u2014SMART 2012\u20132016","volume":"37","author":"Lob","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib31","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.clinthera.2016.04.035","article-title":"Pathogen prevalence and antimicrobial susceptibility among enterobacteriaceae causing hospital-associated intra-abdominal infections in adults in the United States (2012-2013)","volume":"38","author":"Zalacain","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2019.03.030_bib32","first-page":"136","volume":"vol. 31","author":"Cant\u00f3n","year":"2018"},{"key":"10.1016\/j.cmi.2019.03.030_bib33","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.02190-12","article-title":"Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum \u03b2lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model","volume":"57","author":"Docobo-P\u00e9rez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib34","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"45","author":"Thomson","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib35","doi-asserted-by":"crossref","first-page":"O831","DOI":"10.1111\/1469-0691.12677","article-title":"In\u00a0vitro and in\u00a0vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae","volume":"20","author":"Harada","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.030_bib36","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jama.2018.19345","article-title":"Antibiotics for ceftriaxone resistant gram-negative bacterial bloodstream infections","volume":"321","author":"Rodr\u00edguez-Ba\u00f1o","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2019.03.030_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jama.2018.19353","article-title":"Antibiotics for ceftriaxone resistant gram-negative bacterial bloodstream infections-reply","volume":"321","author":"Harris","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2019.03.030_bib38","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ijantimicag.2018.07.021","article-title":"Beta-lactam\/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended spectrum beta-lactamase producing Enterobacteriaceae\u202f: systematic review and meta-analysis","volume":"52","author":"Sfeir","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib39","doi-asserted-by":"crossref","first-page":"ofx09","DOI":"10.1093\/ofid\/ofx099","article-title":"Comparison between carbapenems and beta-lactam\/beta-lactamase inhibitors in the treatment for bloodstream caused by ESBL-producing Enterobacteriaceae: a systematic review and meta-analysis","volume":"4","author":"Muhammed","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib40","doi-asserted-by":"crossref","first-page":"e01813","DOI":"10.1128\/AAC.01813-18","article-title":"Carbapenem versus cefepime or piperacillin-tazobactam for the empiric treatment of extended spectrum \u03b2-lactamase producing Escherichia coli bacteremia in patients with hematologic malignancy","volume":"63","author":"Benanti","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2016.09.027","article-title":"Piperacillin\/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study","volume":"49","author":"Guet-Revillet","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib42","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A\u00a0multinational, preregistered cohort study of B-lactam\/B-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-B-Lactamase-Producing enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib43","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib44","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1001\/archinte.168.17.1897","article-title":"Community infections caused by extended-spectrum beta-lactamase\u2013producing Escherichia coli","volume":"168","author":"Rodriguez-Ba\u00f1o","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2019.03.030_bib45","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jac\/dkl102","article-title":"Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-\u03b2-lactamase-producing Escherichia coli with amoxicillin\/clavulanate: case report and characterization of the isolate","volume":"57","author":"Lagac\u00e9-Wiens","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1469-0691.2009.02893.x","article-title":"Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin \u2013 clavulanate and piperacillin \u2013 tazobactam with","volume":"16","author":"L\u00f3pez-Cerero","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.030_bib47","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/jac\/dky124","article-title":"Efficacy and safety of ceftazidime\/avibactam: a systematic review and meta-analysis","volume":"73","author":"Sternbach","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib49","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib50","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.03.030_bib51","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/508877","article-title":"Bacteremia due to extended-spectrum -Lactamase-Producing Escherichia coli in the CTX-M era: a new clinical challenge","volume":"43","author":"Rodriguez-Bano","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib52","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/jac\/dkw133","article-title":"CTX-M-15-H30Rx-ST131 subclone is one of the main causes of healthcare-associated ESBL-producing Escherichia coli bacteraemia of urinary origin in Spain","volume":"71","author":"Merino","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib53","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JCM.00447-06","article-title":"Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions","volume":"44","author":"Oteo","year":"2006","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.03.030_bib54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1469-0691.2005.01290.x","article-title":"High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients","volume":"12","author":"Goethaert","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.030_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.diagmicrobio.2006.06.015","article-title":"Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"56","author":"Bin","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib56","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib57","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime therapy for cefepime- susceptible extended-spectrum \u03b2-lactamase-producing enterobacteriaceae bacteremia","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijantimicag.2017.09.013","article-title":"Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing enterobacteriaceae","volume":"51","author":"Kim","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib60","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.41.3.563","article-title":"Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC\u202f??-lactamase, and the loss of an outer membrane protein","volume":"41","author":"Bradford","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib61","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/infdis\/159.5.1005","article-title":"In\u00a0vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase","volume":"159","author":"Pangon","year":"1989","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib62","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/JCM.37.12.4020-4027.1999","article-title":"Bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes","volume":"37","author":"Siu","year":"1999","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.03.030_bib63","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1471-2334-12-206","article-title":"Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis","volume":"12","author":"Yang","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib64","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ijantimicag.2015.07.020","article-title":"Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective","volume":"46","author":"Lee","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib65","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.00701-15","article-title":"Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia","volume":"59","author":"Matsumura","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib66","doi-asserted-by":"crossref","first-page":"1105.e1","DOI":"10.1016\/j.cmi.2015.07.025","article-title":"Clinical and microbiologic characteristics of adult patients with recurrent bacteraemia caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli or Klebsiella pneumoniae","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.030_bib67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12879-016-1770-1","article-title":"Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems","volume":"16","author":"Fukuchi","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib68","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/IDR.S146923","article-title":"Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime resistant enterobacteriaceae bacteremia","volume":"11","author":"Lee","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2019.03.030_bib69","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ijantimicag.2018.01.008","article-title":"Cefoxitin-based antibiotic therapy for extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study","volume":"51","author":"Demonchy","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib70","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/jac\/dkl043","article-title":"Activity of temocillin against prevalent ESBL- and AmpC-producing enterobacteriaceae from south-east england","volume":"57","author":"Livermore","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1586\/14787210.4.4.601","article-title":"Treatment options for multidrug-resistant bacteria","volume":"4","author":"Giamarellou","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2019.03.030_bib72","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/jac\/dky101","article-title":"Temocillin against Enterobacteriaceae isolates from community acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods","volume":"73","author":"Alexandre","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib73","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dku542","article-title":"Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15","volume":"70","author":"Soubirou","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib74","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkr317","article-title":"Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and\/or derepressed AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"66","author":"Balakrishnan","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib75","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib76","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Vidal","year":"2007","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib77","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkn469","article-title":"Aminoglycoside drugs in clinical practice: an evidence-based approach","volume":"63","author":"Leibovici","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003344.pub3","article-title":"Cochrane Database of Systematic Reviews Beta lactam antibiotic monotherapy versus beta lactam- aminoglycoside antibiotic combination therapy for sepsis (Review)","author":"Paul","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2019.03.030_bib79","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cix606","article-title":"Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum \u03b2-lactamase-producing enterobacteriaceae: results from the INCREMENT cohort","volume":"65","author":"Palacios-Baena","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib80","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/dkp411","article-title":"Bacteraemia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome","volume":"65","author":"Gudiol","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib81","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1089\/mdr.2014.0092","article-title":"Extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children","volume":"21","author":"Han","year":"2015","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.cmi.2019.03.030_bib82","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3904\/kjim.2016.31.1.156","article-title":"Amikacin therapy for urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"31","author":"Cho","year":"2016","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.cmi.2019.03.030_bib83","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jiac.2014.08.007","article-title":"Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae","volume":"20","author":"Ipekci","year":"2014","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0190910","article-title":"Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: a French prospective multicenter study","volume":"13","author":"Madhi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2019.03.030_bib85","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijantimicag.2018.03.014","article-title":"Which non-carbapenem antibiotics are active against extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae?","volume":"52","author":"Bouxom","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib86","series-title":"Plazomicin [Internet]","year":"2018"},{"key":"10.1016\/j.cmi.2019.03.030_bib87","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/dki291","article-title":"Tigecycline: what is it, and where should it be used?","volume":"56","author":"Livermore","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib88","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1590\/S1413-86702008000300007","article-title":"Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry","volume":"12","author":"Curcio","year":"2008","journal-title":"Braz J. Infect. Dis."},{"key":"10.1016\/j.cmi.2019.03.030_bib89","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/AAC.01402-10","article-title":"Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease","volume":"55","author":"Cai","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib90","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/jac\/dkr242","article-title":"Efficacy and safety of tigecycline: a systematic review and meta-analysis","volume":"66","author":"Yahav","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib91","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1473-3099(11)70177-3","article-title":"Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis","volume":"11","author":"Tasina","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2015.08.009","article-title":"Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs","volume":"39","author":"Shen","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib93","first-page":"273","article-title":"Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens","volume":"58","author":"Poulakou","year":"2009","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2019.03.030_bib94","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329406","article-title":"Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections - new insights into clinical results and treatment practice","volume":"57","author":"Eckmann","year":"2011","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2019.03.030_bib95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s15010-014-0691-4","article-title":"Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria","volume":"43","author":"Heizmann","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2019.03.030_bib96","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1157\/13095372","article-title":"[Activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae]","volume":"24","author":"de Cueto","year":"2006","journal-title":"Enfermedades Infecc y Microbiol cl\u00ednica"},{"key":"10.1016\/j.cmi.2019.03.030_bib97","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1128\/AAC.00721-09","article-title":"Susceptibility of urinary tract bacteria to fosfomycin","volume":"53","author":"Maraki","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib99","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib100","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for injection (ZTI-01) vs piperacillin-tazobactam (PIP-TAZ) for the treatment of complicated urinary tract infection (cUTI) including acute pyelonephritis (AP): ZEUS, a phase 2\/3 randomized trial","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib101","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00752-15","article-title":"Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance","volume":"59","author":"Docobo-P\u00e9rez","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib102","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.1128\/AAC.04955-14","article-title":"Exploration of the pharmacokinetic-pharmacodynamic relationships for fosfomycin efficacy using an in\u00a0Vitro infection model","volume":"59","author":"VanScoy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib103","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2006.08.039","article-title":"Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections","volume":"29","author":"Pullukcu","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.030_bib104","first-page":"355","article-title":"Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli -related complicated lower urinary tract infection","volume":"22","author":"Senol","year":"2010","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib105","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1128\/AAC.02611-15","article-title":"Long-Term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis","volume":"60","author":"Los-Arcos","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib106","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1017\/S0950268816002879","article-title":"High prevalence of fosfomycin resistance gene fosA3 in blaCTX-M-harbouring Escherichia coli from urine in a Chinese tertiary hospital during 2010-2014","volume":"145","author":"Cao","year":"2017","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.cmi.2019.03.030_bib107","first-page":"43","article-title":"Aumento significativo de la resistencia a fosfomicina en cepas de Escherichia coli productoras de \u03b2-lactamasas de espectro extendido (BLEE) aisladas de urocultivos (2005-2009-2011)","volume":"26","author":"Rodr\u00edguez-Avial","year":"2013","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.cmi.2019.03.030_bib108","first-page":"1134","article-title":"Activity of fosfomycin against extended-spectrum-beta-lactamase- producing uropathogens in patients in the community and hospitalized patients","volume":"60","author":"Linsenmeyer","year":"2016"},{"key":"10.1016\/j.cmi.2019.03.030_bib109","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1600-0463.2011.02766.x","article-title":"Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae","volume":"119","author":"Titelman","year":"2011","journal-title":"APMIS"},{"key":"10.1016\/j.cmi.2019.03.030_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2014-007363","article-title":"Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial","volume":"5","author":"Rosso-Fern\u00e1ndez","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2019.03.030_bib111","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1086\/421094","article-title":"Population-Based laboratory surveillance for Escherichia coli\u2013producing extended-spectrum \u03b2-lactamases: importance of community isolates with blaCTX-M genes","volume":"38","author":"Pitout","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib112","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1128\/JCM.43.6.2844-2849.2005","article-title":"Community-wide outbreaks of clonally related CTX-M-14 \u03b2-lactamase- producing Escherichia coli strains in the Calgary Health Region","volume":"43","author":"Pitout","year":"2005","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.03.030_bib113","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/JCM.42.3.1089-1094.2004","article-title":"Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients","volume":"42","author":"Rodr\u00edguez-Ba\u00f1o","year":"2004","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2019.03.030_bib114","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.diagmicrobio.2012.05.024","article-title":"Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study","volume":"74","author":"Hoban","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib115","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.clinthera.2013.03.022","article-title":"Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011","volume":"35","author":"Bouchillon","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2019.03.030_bib116","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.diagmicrobio.2016.04.022","article-title":"Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010\u20132014","volume":"85","author":"Lob","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib117","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.01509-06","article-title":"Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment","volume":"51","author":"Tumbarello","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib118","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/380645","article-title":"Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum \u03b2-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin","volume":"38","author":"Endimiani","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.030_bib119","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/dkm536","article-title":"Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation","volume":"61","author":"Frei","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.030_bib120","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jmii.2015.08.012","article-title":"Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"50","author":"Lo","year":"2017","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.cmi.2019.03.030_bib121","unstructured":"FDA. FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions Title [Internet]. Available from: https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm612995.htm."}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19301557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19301557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:22:36Z","timestamp":1761117756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19301557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":121,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1198743X19301557"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.03.030","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}